HRP20191864T1 - Imunogeni pripravci protiv bakterije clostridium difficile - Google Patents

Imunogeni pripravci protiv bakterije clostridium difficile Download PDF

Info

Publication number
HRP20191864T1
HRP20191864T1 HRP20191864TT HRP20191864T HRP20191864T1 HR P20191864 T1 HRP20191864 T1 HR P20191864T1 HR P20191864T T HRP20191864T T HR P20191864TT HR P20191864 T HRP20191864 T HR P20191864T HR P20191864 T1 HRP20191864 T1 HR P20191864T1
Authority
HR
Croatia
Prior art keywords
protein
immunogenic preparation
clostridium difficile
toxin
isolated
Prior art date
Application number
HRP20191864TT
Other languages
English (en)
Croatian (hr)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20191864T1 publication Critical patent/HRP20191864T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20191864TT 2014-06-25 2015-06-25 Imunogeni pripravci protiv bakterije clostridium difficile HRP20191864T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition
PCT/EP2015/064324 WO2015197737A1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition
EP15733404.6A EP3160500B1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition

Publications (1)

Publication Number Publication Date
HRP20191864T1 true HRP20191864T1 (hr) 2020-01-10

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191864TT HRP20191864T1 (hr) 2014-06-25 2015-06-25 Imunogeni pripravci protiv bakterije clostridium difficile

Country Status (17)

Country Link
US (1) US20170218031A1 (cg-RX-API-DMAC7.html)
EP (2) EP3636278A3 (cg-RX-API-DMAC7.html)
JP (2) JP6688233B2 (cg-RX-API-DMAC7.html)
CN (1) CN106536544B (cg-RX-API-DMAC7.html)
BE (1) BE1022949B1 (cg-RX-API-DMAC7.html)
BR (1) BR112016030096B1 (cg-RX-API-DMAC7.html)
CY (1) CY1122145T1 (cg-RX-API-DMAC7.html)
DK (1) DK3160500T3 (cg-RX-API-DMAC7.html)
ES (1) ES2749701T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191864T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045936T2 (cg-RX-API-DMAC7.html)
LT (1) LT3160500T (cg-RX-API-DMAC7.html)
MX (1) MX374380B (cg-RX-API-DMAC7.html)
PL (1) PL3160500T3 (cg-RX-API-DMAC7.html)
PT (1) PT3160500T (cg-RX-API-DMAC7.html)
SI (1) SI3160500T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015197737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123419B2 (en) * 2017-03-15 2021-09-21 Novavax, Inc. Methods and compositions for inducing immune responses against Clostridium difficile
WO2019243307A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
NZ337543A (en) 1994-10-24 2002-06-28 Allergan Inc Composition comprising avian antitoxin against clostridial neurotoxin protein and method for producing recombinant antitoxin proteins are provided for
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2220530A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. Improved method for obtaining full-length cdna sequences
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2003304316A1 (en) * 2002-11-08 2005-01-28 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
JP6084631B2 (ja) * 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
HRP20190711T1 (hr) * 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni pripravak
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
BR112016030096A8 (pt) 2021-07-06
BR112016030096B1 (pt) 2023-10-03
JP2020100625A (ja) 2020-07-02
BE1022949A1 (fr) 2016-10-21
EP3160500A1 (en) 2017-05-03
DK3160500T3 (da) 2019-11-11
WO2015197737A1 (en) 2015-12-30
BE1022949B1 (fr) 2016-10-21
JP6688233B2 (ja) 2020-04-28
LT3160500T (lt) 2019-10-25
PL3160500T3 (pl) 2020-02-28
HUE045936T2 (hu) 2020-01-28
CN106536544A (zh) 2017-03-22
MX2016017094A (es) 2017-05-03
EP3636278A3 (en) 2020-07-15
EP3636278A2 (en) 2020-04-15
CN106536544B (zh) 2020-04-07
MX374380B (es) 2025-03-06
US20170218031A1 (en) 2017-08-03
BR112016030096A2 (pt) 2017-08-22
ES2749701T3 (es) 2020-03-23
CA2952118A1 (en) 2015-12-30
PT3160500T (pt) 2019-11-11
EP3160500B1 (en) 2019-08-21
JP2017520573A (ja) 2017-07-27
SI3160500T1 (sl) 2019-11-29
CY1122145T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
HRP20191291T1 (hr) Imunogeni pripravak
HRP20200727T1 (hr) Pripravci i metode povezane s varijantama proteina a (spa)
WO2015024668A3 (en) Respiratory syncytial virus (rsv) vaccine
EA201890355A1 (ru) Новые способы индукции иммунного ответа
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
SI2707393T1 (en) Fusion proteins and combined vaccines comprising protein E and AH haemophilus influenzae
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
MX2016015821A (es) Composicion de vacuna contra infeccion por streptococcus suis.
HRP20181102T1 (hr) Cjepiva za hsv-2
CA2856891C (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX376079B (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
MX2016002937A (es) Vacuna oncologica.
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2015107363A3 (en) Mycobacterial antigen composition
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
HRP20220064T1 (hr) Zglobno modificirani fragmenti protutijela i postupci za pripravu
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
HRP20191864T1 (hr) Imunogeni pripravci protiv bakterije clostridium difficile
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком